ABAT | 4-aminobutyrate aminotransferase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
ABL1 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ADA | Adenosine deaminase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
ADH1A | Alcohol dehydrogenase 1A (class I), alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
ADH1B | Alcohol dehydrogenase 1B (class I), beta polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
ADH1C | Alcohol dehydrogenase 1C (class I), gamma polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
ADK | Adenosine kinase | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Group enriched |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
AKR1D1 | Aldo-keto reductase family 1, member D1 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enriched |
ALAD | Aminolevulinate dehydratase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
ALPPL2 | Alkaline phosphatase, placental-like 2 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AMY2A | Amylase, alpha 2A (pancreatic) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
ANXA1 | Annexin A1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
APEX1 | APEX nuclease (multifunctional DNA repair enzyme) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
AR | Androgen receptor | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
ATP6V1B2 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Expressed in all |
BCL2 | B-cell CLL/lymphoma 2 | Cancer-related genes Disease related genes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
BCR | Breakpoint cluster region | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
BLVRB | Biliverdin reductase B (flavin reductase (NADPH)) | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
BRAF | B-Raf proto-oncogene, serine/threonine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CA1 | Carbonic anhydrase I | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
CA3 | Carbonic anhydrase III, muscle specific | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CAT | Catalase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CCND1 | Cyclin D1 | Cancer-related genes Disease related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHD1 | Chromodomain helicase DNA binding protein 1 | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CHRM1 | Cholinergic receptor, muscarinic 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |